Hansoh Pharmaceutical Announces Nintedanib Esilate Soft Capsules Receives Drug Registration Certificate in China

　　Hansoh Pharma(03692) announced that "Nintedanib Ethanesulfonate Soft Capsules," developed by its subsidiary Jiangsu Hansoh Pharmaceutical Group Co., Ltd., has been granted a drug registration certificate by the China National Medical Products Administration.

This product is a kinase inhibitor indicated for systemic sclerosis-associated interstitial lung disease and chronic fibrosing interstitial lung disease with a progressive phenotype.

The product's receipt of the drug registration certificate will further enrich and improve the group's product portfolio.

Editor: Lu Yu-Jun